Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the Sponsor.
On 11 January 2016, orphan designation (EU/3/15/1607) was granted by the European Commission to TMC Pharma Services Ltd, United Kingdom, for entolimod for the treatment of acute radiation syndrome.
The sponsorship was transferred to TMC Pharma (EU) Limited, Ireland, in February 2019.
|Disease / condition||
Treatment of acute radiation syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.